Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest’s Combunox Approved

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest's combination pain therapy Combunox was approved by FDA, the company said Nov. 26

You may also be interested in...



Combunox's Future At Forest May Depend On Success Of New Trial Program

The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested

Combunox's Future At Forest May Depend On Success Of New Trial Program

The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested

Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window

The company licenses U.S. and Canadian rights to Phase II plasminogen activator, derived from vampire bat saliva, from German firm PAION GmbH; desmoteplase is Forest’s first biologic product. The companies expect to initiate the rolling BLA submission as early as 2007.

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel